Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.39 |
| ▸ | JAK1 | P23458 | 2/20 | 0.37 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.36 |
| ▸ | JAK2 | O60674 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.35 |
| ▸ | DPP4 | P27487 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2328812 | 0.87 | CTSK (0.43) | CTSKMEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL25305211 | 0.86 | CTSK (0.42) | CTSKMEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL1707010 | 0.86 | CTSK (0.42) | CTSKMEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL17830842 | 0.84 | USP2 (0.45) | CTSKMEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL2943268 | 0.82 | NR1H2 (0.44) | CTSKMEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL27330332 | 0.82 | CTSK (0.39) | CTSKMEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL1706650 | 0.81 | USP2 (0.43) | CTSKMEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL15577456 | 0.81 | CTSK (0.38) | CTSKMEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL15577439 | 0.81 | CTSK (0.38) | CTSKMEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL27329692 | 0.80 | CTSK (0.38) | CTSKMEN1ALDH1A1MAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8518945-B2 | Pyrrolopyrazine kinase inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2013-08-27 | — | — | US | disclosed |
| EP-2550273-A2 | PYRROLOPYRAZINE KINASE INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2013-01-30 | — | — | EP | disclosed |
| WO-2011117145-A2 | PYRROLOPYRAZINE KINASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-09-29 | — | — | WO | disclosed |
| US-20110230462-A1 | Pyrrolopyrazine Kinase Inhibitors | HENDRICKS ROBERT THAN | 2011-09-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110230462-A1 | Pyrrolopyrazine Kinase Inhibitors | SYK, ZAP70, BTK | CTSK 834/4885MEN1 4109/4885ALDH1A1 4643/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.